News
- Author:
- Sue Hughes
Publish date: January 14, 2022
Although the inflammation improved over time in the study, the long-term consequences are not known, the authors warn.
News
- Author:
- Sue Hughes
Publish date: January 7, 2022
Intramyocardial hemorrhage could be a major cause of reperfusion injury after MI and could contribute to myocardial damage.
News
- Author:
- Sue Hughes
Publish date: December 10, 2021
One-third of cardiologist trainees in the U.K. reported experiencing or witnessing bullying in the previous 4-week period in new survey, with the m...
News
- Author:
- Sue Hughes
Publish date: December 3, 2021
“Came back from a conference in London. With a mask and 3 Pfizer vaccines I managed to get Omicron.”
News
- Author:
- Sue Hughes
Publish date: December 2, 2021
A new lipid-lowering agent, obicetrapib, in a class that had been written off by many, is being developed by a group of academic experts, with new ...
News
- Author:
- Sue Hughes
Publish date: November 16, 2021
A high dose of the purified form of eicosapentaenoic acid failed to significantly reduce hospitalizations or deat...
News
- Author:
- Sue Hughes
Publish date: November 13, 2021
A new randomized trial showed similar rates of severe bleeding in patients going to surgery at 3 days and 6 days after stopping the antiplatelet me...
News
- Author:
- Sue Hughes
Publish date: November 5, 2021
A new study suggests that less than a third of U.S. patients with stable ischemic heart disease who currently undergo intervention would meet the t...
News
- Author:
- Sue Hughes
Publish date: October 29, 2021
Researchers conducted an indirect treatment comparison on the efficacy of the three FDA-approved treatment options for adults with AQP4+ NMOSD.
News
- Author:
- Sue Hughes
Publish date: October 26, 2021
The procedure was associated with a slowing of disability progression and a higher likelihood of disability improvement.
News
- Author:
- Sue Hughes
Publish date: October 25, 2021
The updated guidelines address the efficacy of disease-modifying therapies, early treatment decisions, disease/treatment response monitoring and tr...
News
- Author:
- Sue Hughes
Publish date: October 19, 2021
The document proposes a global vaccination strategy for the general MS patient population and selected subpopulations.
News
- Author:
- Sue Hughes
Publish date: October 18, 2021
The statement concludes that the COVID-19 vaccines that are currently available are safe for patients with MS.
News
- Author:
- Sue Hughes
Publish date: October 15, 2021
Trial data are being used to support a recent approval application to the FDA for ublituximab to treat patients with relapsing remitting MS.
News
- Author:
- Sue Hughes
Publish date: October 14, 2021
Currently approved COVID-19 vaccines appear safe in patients with MS and are effective in most patients.
